Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology (Nasdaq: VIR) has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta (CHD) with the enrollment of the first participant in ECLIPSE 3. The Phase 2b ECLIPSE 3 trial will evaluate the combination of tobevibart and elebsiran compared to bulevirtide in CHD patients.
The combination therapy has received multiple regulatory designations including Breakthrough Therapy and Fast Track from the FDA, and PRIME and orphan drug status from the EMA. The treatment aims to eliminate the virus through multiple mechanisms, addressing an urgent unmet medical need in CHD, which is the most severe form of chronic viral hepatitis with no approved treatments in the U.S.
Vir Biotechnology (Nasdaq: VIR) has initiated ECLIPSE 2, a pivotal Phase 3 clinical trial for chronic hepatitis delta (CHD). The trial will evaluate the combination of tobevibart and elebsiran versus continued bulevirtide monotherapy in patients who haven't achieved undetectable hepatitis delta virus RNA with bulevirtide treatment.
ECLIPSE 2 is part of Vir's global ECLIPSE registrational program launched in March 2025, designed to support marketing applications in the U.S. and Europe. The combination therapy has received multiple regulatory designations, including FDA Breakthrough Therapy and Fast Track, and EMA PRIME and orphan drug designations.
Vir Biotechnology (Nasdaq: VIR) has initiated dosing in a Phase 1 clinical trial for VIR-5525, their third dual-masked T-cell engager targeting EGFR for solid tumors. The trial will evaluate the treatment in multiple cancer types including NSCLC, colorectal cancer, HNSCC, and cSCC.
The study will assess VIR-5525 both as monotherapy and in combination with pembrolizumab. The drug leverages the PRO-XTEN™ masking technology to selectively activate in tumor environments, potentially reducing toxicity. The first patient dosing triggers a $75 million milestone payment from Sanofi under their 2024 licensing agreement.
Additionally, the company reported continued dose escalation for their other dual-masked TCEs (VIR-5818 for HER2 and VIR-5500 for PSMA), with promising early clinical responses and safety data from January 2025.
Vir Biotechnology (Nasdaq: VIR) has scheduled its second quarter 2025 financial results announcement and corporate update for August 6, 2025. The company will release its financial results and corporate update via press release after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Investors can access the conference call through a webcast on Vir's website or by phone using the toll-free number +1 (888) 800-8770 or international number +1 (646) 307-1953 with Conference ID: 7568777. A recording will be available approximately two hours after the event and archived for 30 days.
Vir Biotechnology (VIR) announced that its CEO Marianne De Backer will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The event is scheduled for June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the discussion will be available in the Investors section of Vir's website under Events & Presentations and will remain archived for 30 days.
Vir Biotechnology (VIR) announced that CEO Marianne De Backer and EVP Mika Kakefuda Derynck will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:30 PM PT / 4:30 PM ET. The event will be accessible via webcast in the Investors section of Vir's website under Events & Presentations and will remain archived for 30 days.
Vir Biotechnology (VIR) announced that CEO Marianne De Backer will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference. The event is scheduled for Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Investors can access a live webcast of the presentation through the Events & Presentations section of Vir's website, where it will remain archived for 30 days.
Vir Biotechnology has scheduled its first quarter 2025 financial results announcement and corporate update for May 7, 2025. The company will release its Q1 2025 results and corporate updates via press release shortly after market close.
A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on the same day. Stakeholders can access the call through:
- Webcast: Events & Presentations page on Vir's website
- Phone: U.S. toll-free at +1 (888) 800-8770
- International: +1 (646) 307-1953
- Conference ID: 7568777
The recorded version will be available approximately two hours after the event and will remain accessible for 30 days.